Overview

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, and recommended phase 2 dose of oral ridaforolimus administered in combination with intravenous bevacizumab in patients with advanced cancers.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Collaborator:
Ariad Pharmaceuticals
Treatments:
Bevacizumab
Sirolimus